Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.

Breit MN, Kisseberth WC, Bear MD, Landesman Y, Kashyap T, McCauley D, Kauffman MG, Shacham S, London CA.

BMC Vet Res. 2014 Jul 15;10:160. doi: 10.1186/1746-6148-10-160.

2.

Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.

Yang J, Bill MA, Young GS, La Perle K, Landesman Y, Shacham S, Kauffman M, Senapedis W, Kashyap T, Saint-Martin JR, Kendra K, Lesinski GB.

PLoS One. 2014 Jul 24;9(7):e102983. doi: 10.1371/journal.pone.0102983. eCollection 2014.

3.

Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.

London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, Wilson H, Jensen K, Ito D, Modiano JF, Bear MD, Pennell ML, Saint-Martin JR, McCauley D, Kauffman M, Shacham S.

PLoS One. 2014 Feb 4;9(2):e87585. doi: 10.1371/journal.pone.0087585. eCollection 2014.

4.

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.

De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, Friedlander S, Landesman Y, Kauffman MG, Shacham S, Pennati M, Zaffaroni N.

Oncotarget. 2015 May 30;6(15):13119-32.

5.

KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.

Zheng Y, Gery S, Sun H, Shacham S, Kauffman M, Koeffler HP.

Cancer Chemother Pharmacol. 2014 Sep;74(3):487-95. doi: 10.1007/s00280-014-2495-8. Epub 2014 Jul 17.

6.

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.

Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R.

Blood. 2012 Aug 30;120(9):1765-73. doi: 10.1182/blood-2012-04-423160. Epub 2012 Jun 7.

7.

Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.

Wettersten HI, Landesman Y, Friedlander S, Shacham S, Kauffman M, Weiss RH.

PLoS One. 2014 Dec 2;9(12):e113867. doi: 10.1371/journal.pone.0113867. eCollection 2014.

8.

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.

Green AL, Ramkissoon SH, McCauley D, Jones K, Perry JA, Hsu JH, Ramkissoon LA, Maire CL, Hubbell-Engler B, Knoff DS, Shacham S, Ligon KL, Kung AL.

Neuro Oncol. 2015 May;17(5):697-707. doi: 10.1093/neuonc/nou303. Epub 2014 Nov 2.

PMID:
25366336
9.

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, Tiedemann RE, Palmer SE, Garbitt VM, McCauley D, Kauffman M, Shacham S, Chesi M, Bergsagel PL, Stewart AK.

Leukemia. 2013 Dec;27(12):2357-65. doi: 10.1038/leu.2013.172. Epub 2013 Jun 11.

10.

Nucleo-cytoplasmic transport as a therapeutic target of cancer.

Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C.

J Hematol Oncol. 2014 Dec 5;7:85. doi: 10.1186/s13045-014-0085-1. Review.

11.

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D.

Blood. 2013 Oct 24;122(17):3034-44. doi: 10.1182/blood-2013-04-495374. Epub 2013 Aug 22.

12.

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.

Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K.

Cancer Sci. 2014 Jul;105(7):795-801. doi: 10.1111/cas.12430. Epub 2014 Jun 3.

13.

XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).

Gravina GL, Tortoreto M, Mancini A, Addis A, Di Cesare E, Lenzi A, Landesman Y, McCauley D, Kauffman M, Shacham S, Zaffaroni N, Festuccia C.

J Hematol Oncol. 2014 Oct 5;7:46. doi: 10.1186/1756-8722-7-46.

14.

XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.

Cheng Y, Holloway MP, Nguyen K, McCauley D, Landesman Y, Kauffman MG, Shacham S, Altura RA.

Mol Cancer Ther. 2014 Mar;13(3):675-86. doi: 10.1158/1535-7163.MCT-13-0416. Epub 2014 Jan 15.

15.

CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.

Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC.

Mol Cancer Ther. 2013 Jul;12(7):1171-9. doi: 10.1158/1535-7163.MCT-12-1171. Epub 2013 Apr 24.

16.

SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.

Gerecitano J.

J Hematol Oncol. 2014 Oct 4;7:67. doi: 10.1186/s13045-014-0067-3.

17.

Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts.

Wang S, Han X, Wang J, Yao J, Shi Y.

PLoS One. 2014 Mar 4;9(3):e89848. doi: 10.1371/journal.pone.0089848. eCollection 2014.

18.

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer.

Gao J, Azmi AS, Aboukameel A, Kauffman M, Shacham S, Abou-Samra AB, Mohammad RM.

Oncotarget. 2014 Jun 15;5(11):3444-54.

19.

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.

Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A.

Br J Haematol. 2013 Apr;161(1):117-27. doi: 10.1111/bjh.12231. Epub 2013 Feb 4.

20.

Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice.

Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, Shacham S, Mohammad RM.

Gastroenterology. 2013 Feb;144(2):447-56. doi: 10.1053/j.gastro.2012.10.036. Epub 2012 Oct 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk